Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ching

Showing results (141-150 of 217) with videos related to

Pageof 22
Sort By:
Cancer Chemotherapy and Pharmacology|May 11, 2001
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenacS Zhou, J W Paxton, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomideS Zhou, P Kestell, M D Tingle, et al.
JAMA|November 26, 1999
Statewide system of electronic notifiable disease reporting from clinical laboratories: comparing automated reporting with conventional methodsP Effler, M Ching-Lee, A Bogard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptorJ H Pang, Z Cao, W R Joseph, et al.
Journal of Applied Microbiology|August 17, 2000
Alterations in extracellular substances during the biofilm development of Pseudomonas aeruginosa on aluminum platesH Y Cheung, S Q Sun, B Sreedhar, et al.
Cancer Research|March 31, 2001
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor fociJ R Kanwar, R K Kanwar, S Pandey, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccinesRobert W Kaminski, K Ross Turbyfill, C Chao, et al.
Adolescence|December 3, 2009
Evaluation of a school-based internship program for Chinese immigrant adolescents in the United StatesAlison M Ching, Christine J Yeh, Wing Yin Siu, et al.
Annals of the New York Academy of Sciences|July 16, 2003
Genomic studies of Rickettsia prowazekii virulent and avirulent strainsH Ge, Y-Y E Chuang, S Zhao, et al.
British Journal of Cancer|January 1, 1997
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)M Philpott, W R Joseph, K E Crosier, et al.
Pageof 22

Showing results (141-150 of 217) with videos related to

Sort By:
Pageof 22
Cancer Chemotherapy and Pharmacology|May 11, 2001
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenacS Zhou, J W Paxton, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomideS Zhou, P Kestell, M D Tingle, et al.
JAMA|November 26, 1999
Statewide system of electronic notifiable disease reporting from clinical laboratories: comparing automated reporting with conventional methodsP Effler, M Ching-Lee, A Bogard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptorJ H Pang, Z Cao, W R Joseph, et al.
Journal of Applied Microbiology|August 17, 2000
Alterations in extracellular substances during the biofilm development of Pseudomonas aeruginosa on aluminum platesH Y Cheung, S Q Sun, B Sreedhar, et al.
Cancer Research|March 31, 2001
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor fociJ R Kanwar, R K Kanwar, S Pandey, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccinesRobert W Kaminski, K Ross Turbyfill, C Chao, et al.
Adolescence|December 3, 2009
Evaluation of a school-based internship program for Chinese immigrant adolescents in the United StatesAlison M Ching, Christine J Yeh, Wing Yin Siu, et al.
Annals of the New York Academy of Sciences|July 16, 2003
Genomic studies of Rickettsia prowazekii virulent and avirulent strainsH Ge, Y-Y E Chuang, S Zhao, et al.
British Journal of Cancer|January 1, 1997
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)M Philpott, W R Joseph, K E Crosier, et al.
Pageof 22